Paratek Pharms Inc Drug Patent Portfolio
Paratek Pharms Inc owns 1 orange book drug protected by 11 US patents Given below is the list of Paratek Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10383884 | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) | 31 Oct, 2037 | Active |
| US10835542 | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) | 31 Oct, 2037 | Active |
| US10111890 | 9-aminomethyl minocycline compounds and uses thereof | 03 Aug, 2037 | Active |
| US9314475 | Oral and injectable formulations of tetracycline compounds | 18 Mar, 2031 | Active |
| US9265740 | Minocycline compounds and methods of use thereof | 24 Oct, 2030 | Active |
| US8383610 | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline | 23 Sep, 2030 | Active |
| US10124014 | Minocycline compounds and methods of use thereof | 05 Mar, 2029 | Active |
| US9724358 | Minocycline compounds and methods of use thereof | 05 Mar, 2029 | Active |
| US7553828 | 9-aminomethyl substituted minocycline compounds | 02 Jun, 2025 | Active |
| US7326696 | Amino-methyl substituted tetracycline compounds | 24 Sep, 2023 | Expired |
| US9365500 | 9-aminomethyl substituted minocycline compounds | 29 Jun, 2021 | Expired |
Latest Legal Activities on Paratek Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Paratek Pharms Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 May, 2024 | US10835542 |
|
Interim Patent Term Extension Granted
Critical
| 13 May, 2024 | US7553828 |
| Court Processing Terminated | 17 Apr, 2024 | US7553828 |
| transaction for FDA Determination of Regulatory Review Period | 18 Jan, 2024 | US7553828 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US7553828 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Oct, 2023 | US9314475 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Feb, 2023 | US10383884 |
|
Interim Patent Term Extension Granted
Critical
| 17 Feb, 2023 | US7553828 |
| Second letter to regulating agency to determine regulatory review period | 17 Feb, 2023 | US7553828 |
|
Case Docketed to Examiner in GAU
Critical
| 05 Oct, 2022 | US7553828 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 May, 2022 | US10124014 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 May, 2022 | US10111890 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Feb, 2021 | US9724358 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 30 Dec, 2020 | US7553828 |
|
Recordation of Patent Grant Mailed
Critical
| 17 Nov, 2020 | US10835542 |
Paratek Pharms Inc Drug Patents' Oppositions Filed in EPO
Paratek Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 28, 2021, by Lederer & Keller Patentanwälte Partnerschaft Mbb. This opposition was filed on patent number EP18158017A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP18158017A | May, 2021 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
Paratek Pharms Inc's Family Patents
Paratek Pharms Inc drugs have patent protection in a total of 40 countries. It's US patent count contributes only to 21.2% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Paratek Pharms Inc Drug List
Given below is the complete list of Paratek Pharms Inc's drugs and the patents protecting them.
1. Nuzyra
Nuzyra is protected by 11 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10383884 | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
31 Oct, 2037
(12 years from now)
| Active |
| US10835542 | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
31 Oct, 2037
(12 years from now)
| Active |
| US10111890 | 9-aminomethyl minocycline compounds and uses thereof |
03 Aug, 2037
(12 years from now)
| Active |
| US9314475 | Oral and injectable formulations of tetracycline compounds |
18 Mar, 2031
(5 years from now)
| Active |
| US9265740 | Minocycline compounds and methods of use thereof |
24 Oct, 2030
(5 years from now)
| Active |
| US8383610 | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
23 Sep, 2030
(5 years from now)
| Active |
| US10124014 | Minocycline compounds and methods of use thereof |
05 Mar, 2029
(3 years from now)
| Active |
| US9724358 | Minocycline compounds and methods of use thereof |
05 Mar, 2029
(3 years from now)
| Active |
| US7553828 | 9-aminomethyl substituted minocycline compounds |
02 Jun, 2025
(20 days from now)
| Active |
| US7326696 | Amino-methyl substituted tetracycline compounds |
24 Sep, 2023
(1 year, 7 months ago)
| Expired |
| US9365500 | 9-aminomethyl substituted minocycline compounds |
29 Jun, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nuzyra's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List